Biological Products, (No Diagnostic Substances) · SAN CARLOS, CA, United States
$19.84
-0.85% (-$0.17)2026-08-10
Smart-Money SignalNeutral · 51/100— Insiders are net buyers over 90 days ($6.5M, 5 buys vs 4 sales)
Price Performance
Historical data including institutional events
Company Profile
T
Tao Fu
CEO & Executive Director
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The companyâs products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4Ã7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohnâs disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
- Founded
- 2023
- Employees
- 44
- Headquarters
- SAN CARLOS, CA, United States
- Website
- www.attovia.com
Peer ComparisonRevenue ($B)
▾Loading company sections...